CA15-3, Human (Cancer Antigen 15-3) BioAssay(TM) ELISA Kit

Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year. Roughly half of these newly diagnosed patients are node-negative, however 30% of these cases progress to metastatic disease. There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 is more sensitive than CEA in early detection of breast cancer recurrence. In combination with CA125, CA15-3 has been shown to be useful in early detection of relapse of ovarian cancer. CA15-3 levels are also increased in colon, lung and hepatic tumors. \n\nSample Type: \nSerum\n\nIntended Use: \nFor the quantitative determination of the Cancer Antigen CA15-3 concentration in human serum.\n\nKit Components:\nMicrotiter plate with 1x96 wells.\nMurine Monoclonal Anti-CA15-3 coated\n\nSample Diluent, 1x100ml\n\nEnzyme Conjugate Concentrate (22X), 1x1ml \n\nEnzyme Conjugate Diluent, 1x21ml \n\nStandard , 0unit/ml, 1x1vial\nStandard, 15unit/ml, 1x1vial\nStandard, 30unit/ml, 1x1vial\nStandard, 60unit/ml, 1x1vial\nStandard, 120unit/ml, 1x1vial\nStandard, 240Unit/ml, 1x1vial. \nWash Buffer Concentrate (20X), 1x50ml\nTMB Reagent (One-Step), 1x11ml\nStop Solution (1N HCl), 1x11ml \n\nStorage and Stability:\nStore all components at 4 degrees C. Stable for at least 6 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

C0050-24H

Size

1Kit

References

1 Aziz DC. Quantitation of estrogen and progesterone receptors by immunocytochemical and image analyses. A J Clin Pathol 1992;98:105-11 2 Aziz DC, Peter JB. DNA ploidy and cell-cycle analysis. Tools for\nassessment of cancer prognosis. J Clin Pathol 1991;5:422-38. 3 Clark GM, Dressler LG, Owens MA, Dounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-33. Page 3 4 Elledge RM, McGuire WL. Prognostic factors and therapeutic decisions in axillary node-negative breast cancer. Annu Rev Med\n1993;44:201-10. 5 Foekens JA, Rio C, Seguin P, et al. Prediction of relapse and survival in breast cancer patients by pS2 protein. Cancer Res 1990; 50-3832-7. 6 Isola J, Visakorp T, Holli K, Kallionieml D. Association of p53 expression with other prognostic factors and long term survival in node-negative breast cancer. J Cell Biochem 1992;(Suppl 16D):101. 7 Kute TE, Shao ZM, Snugg NK, Long RT, Russell GB, Case LD. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res 1992;52-198-203. 8 McGuire WL, Tandon AK, Allred D, Chamnes GC, Clark GM. How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 1990;82:1006-7. 9 Nicholson S, Richard J, Sainsbury C, et al. Epidermal growth factor receptor (EGFr): results of a 6 year follow up study in operable breast cancer with emphasis on the node-negative subgroup. Br J Cancer 1991;63:146-50. 10 Somerville JE, Clarke LA, Biggart JD. C-erb B-2 overexpression and histological type of in-situ and invasive breast carcinoma. J Clin Pathol 1992;45-16-20.\n11 Ueronese S, Gambacorta M. Detection of Ki-67 rate in breast cancer. Am J Clin Pathol 1991;95:30-4.\n12 Lotnicker M, Pavesi F, Scarabelli M. Tumor associated antigens CA15-3 and CA125 in ovarian cancer. Int. J. Biolog Markers 1991; 6:115 012609.